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Despite major advances in monitoring technology and knowledge of fetal and neonatal pathophysiology, neonatal hypoxic-
ischemic encephalopathy (HIE) remains one of the main causes of severe adverse neurological outcome in children. Until recently,
there were no therapies other than supportive measures. Over the past several years, mild hypothermia has been proven to be
safe to treat HIE. Unfortunately, this neuroprotective strategy seems eﬃcient in preventing brain injury in some asphyxiated
newborns, but not in all of them. Thus, there is increasing interest to rapidly understand how to reﬁne hypothermia therapy
and add neuroprotective or neurorestorative strategies. Several promising newer treatments to treat birth asphyxia and prevent
its devastating neurological consequences are currently being tested. In this paper, the physiopathology behind HIE, the currently
available treatment, the potential alternatives, and the next steps before implementation of these other treatments are reviewed.
1.Introduction
Hypoxic-ischemic encephalopathy (HIE) is a serious brain
injury due to birth asphyxia [1, 2]. HIE has a variety of
perinatal causes of interrupted uterine and fetal blood ﬂow
and/orhypoxia,suchasuterinerupture,placentalabruption,
andcordprolapse.However,mostoften,theexacttimingand
underlying cause remain unknown [3–5]. Its severity is also
variable. Despite major advances in monitoring technology
and knowledge of fetal and neonatal pathophysiology, birth
asphyxia remains a serious condition that causes signiﬁcant
mortality and long-term morbidity. Causing 23% of all
neonatal deaths worldwide [6, 7], it is one of the top 20
leading causes of burden of disease in all age groups (in
terms of disability life adjusted years) by the World Health
Organization [7]. Most deaths occur in the ﬁrst week of life
duetomultipleorganfailureorwithdrawalofcareduetothe
prospect of severe neurological impairments [8]. Moreover,
children who survive birth asphyxia develop problems such
as cerebral palsy, mental retardation, learning diﬃculties,
and other disabilities [9].
Until recently, there were no therapies other than
supportive measures for perinatal HIE. In the past several
years, studies have been carried out to address the safety
and eﬃcacy of cooling in HIE [10–18]. Unfortunately, this
neuroprotective strategy seems eﬃcient in preventing brain
injury in some asphyxiated newborns, but not in all of them.
Thus, there is an increasing interest to rapidly understand
the degree of brain injury and to possibly reﬁne individual
neuroprotective strategies or add neurorestorative strategies
[19–23]. In this paper, the physiopathology behind HIE,
the current available treatment, the potential alternatives,
and the next steps before implementation of these other
treatments are reviewed.
2. What Is Hypoxic-IschemicEncephalopathy?
Neonatal brain hypoxic-ischemic injury is an evolving
process initiated by the hypoxic-ischemic insult leading to
decreasedbloodﬂowtothebrain(primarylesions),followed
by the restoration of blood ﬂow in an injured brain and
the initiation of a cascade of pathways (secondary lesions,
“reperfusion injury”). This cascade includes accumulation of
extracellularglutamatewithexcessiveactivationofglutamate
receptors, calcium inﬂux, and generation of reactive oxygen
and nitrogen species, leading to cell death and deﬁnitive
brain injuries [24]. This cascade is a primary target for
neuroprotective interventions, but such interventions are
currently limited by insuﬃcient knowledge of the timing and2 International Journal of Pediatrics
Table 1: Potential therapies to treat birth asphyxia in newborns.
Neuroprotective therapies:
Hypothermia
Drugs that might produce a synergistic neuroprotective eﬀect
with hypothermia:
(i) anticonvulsant or antiexcitatory drugs: for example,
phenobarbital, topiramate, bumetanide, magnesium sulphate,
xenon
(ii) anti-apoptotic drugs: for example, erythropoietin
(iii) anti-calcium drugs: for example, xenon
(iv) anti-inﬂammatory or antioxidative drugs: for example,
melatonin, N-acetylcysteine
Neurorestorative therapies:
(i) erythropoietin
(ii) cord blood and mesenchymal stem cells
duration of the so-called therapeutic window in newborns
[19, 21, 22].
3. What Is the CurrentAvailable Treatment?
As the only neuroprotective treatment to have been clinically
tested in large randomized controlled trials to minimize
braininjuryinasphyxiatedtermnewborns[10,11,13,14,17,
18],coolingisthoughttobeprotectiveinnewborns(Table 1)
mainly by reducing brain perfusion and metabolism, as
well as mitigating reperfusion injury, reducing excessive free
radical production, depressing the immune response and
various potentially harmful proinﬂammatory reactions, and
suppress epileptic activity [25]. Some results also suggest
that moderate hypothermia can prevent or delay apoptosis
and might be able to extend the therapeutic window for
other interventions [25]. Results of these clinical trials in
newborns have shown that moderate hypothermia after
birth asphyxia reduces the risk of death and disability at 18
months, with a number needed to treat of nine asphyxiated
newborns to prevent brain injury in one of them [12, 15,
16]. There was no real diﬀerence in any of the outcomes
between whole-body cooling versus selective head cooling
[12, 15, 16]. Only little adverse aﬀects have been observed
with this therapy; the main ones were arrhythmia and
thrombocytopenia [12, 15, 16]. However, it remains unclear
why induced hypothermia seems eﬀective in preventing
brain injury and improving neurological outcome in some
asphyxiated newborns (mainly those with moderate HIE),
but not in others (mainly those with severe HIE) [11, 14].
A better understanding of why brain injury continues to
develop despite hypothermia treatment in some asphyxiated
newborns is required in order to create and test some
more speciﬁcally adjunctive therapies. Furthermore, early
identiﬁcation of patients who will develop further brain
injury despite this treatment would be of utmost importance
in order to determine those who would beneﬁt most from
adjustmentsintheirhypothermiatherapyorfromadjunctive
neuroprotective or neurorestorative therapies [20, 23].
According to the trials described above, mild hypother-
mia to an esophageal temperature of 33.5◦C must be started
in an asphyxiated newborn within 6 hours of life and contin-
ued for 72 hours. This temperature and this timing are based
on animal data; for example the 6-hour limit for cooling
initiation comes from data suggesting that the eﬀectiveness
of cooling diminishes as time increases from the hypoxic-
ischemiceventtoinitiation ofcooling,withtheclosingofthe
“window” at a time between 5.5 and 8 hours after the event
[26]. However, as previously mentioned, the exact timing of
the“therapeuticwindow”isnotknowninhumannewborns.
Some authors are thus starting to suggest that there might
be a beneﬁt from later initiation of cooling and increased
depthordurationofcooling,aswellasprolongedrewarming
strategies [19]. Determination of the exact timing of the
“therapeutic window” in asphyxiated newborns needs to be
further investigated [27]. Additional randomized controlled
trials are required to test if adjustments of current guidelines
of moderate hypothermia for asphyxiated newborns might
be useful to prevent even more eﬃciently brain injury in
these patients. Such trials are currently ongoing (e.g., “late
hypothermia for hypoxic-ischemic encephalopathy,” Clini-
calTrials.gov Identiﬁer: NCT00614744), and results should
be known in the near future.
One of the main challenges of the current guidelines for
cooling newborns with HIE is to initiate the hypothermia
within the ﬁrst 6 hours of birth. In many places around
the world, newborns may be born at great distances from
neonatal intensive care units oﬀering cooling, preventing
them from arriving there within the good timing. Speciﬁc
protocols have to be developed in collaboration with the
cooling centers of reference in order to start cooling safely
and reliably prior to the transport at the birthing center
and/or during transport, so that these patients can also
beneﬁt from this treatment [16, 19, 28]. In particular,
continuousmeasurementofcentraltemperature(esophageal
or rectal) should be carefully monitored, in order to target
the recommended temperature [16, 19, 28].
4. What Arethe PotentialAlternatives?
Studies of alternative treatments for neonatal HIE are
becoming available, with the goal of further increasing the
proven beneﬁts of hypothermia, that is, to decrease eventual
neonatal brain injury associated with neonatal asphyxia
and thus improve future neurodevelopmental outcome.
These alternatives include speciﬁc brain-oriented therapies,
which are targeted to the critical events contributing to
tissue damage in neonatal HIE (Table 1)[ 29]. They usu-
ally involve molecules that cross the blood-brain barrier
and target mechanisms of injury, which are not (or are
not completely) inhibited by hypothermia. These include
anticonvulsant or antiexcitatory drugs (e.g., phenobarbital,
topiramate, bumetanide, magnesium sulphate, and xenon),
antiapoptotic drugs (e.g., erythropoietin), anticalcium drugs
(e.g., xenon), or anti-inﬂammatory or antioxidative drugs
(e.g., melatonin and N-acetylcysteine) [30–33]. The goal
of these experimental therapies is to produce a synergistic
neuroprotective eﬀect with hypothermia [30–33].International Journal of Pediatrics 3
Most research eﬀorts in neonatal neurology are currently
targeted to neuroprotective strategies, but another concept is
slowly emerging from the adult stroke literature. In adults,
neurorestorative therapies (Table 1) are currently being
developed to treat ischemic brain injury, including cerebral
vasculature-based therapy combined with neuroprotection
[34], as the more “conventional” strategies (antiapoptosis,
anticalcium, anti-inﬂammation, and antioxidative injury)
have been disappointingly ineﬀective in adult clinical trials.
These neurorestorative therapies target the neurovascular
unit, composed of functionally integrated cellular (including
brain endothelial cells, astrocytes, pericytes and smooth
muscle cells, neural stem cells, oligodendrocytes, and neu-
rons) and acellular elements that form the basement mem-
brane [35]. Thus, they lead to enhancement of restorative
events, such as endogenous neurogenesis, angiogenesis,
axonal sprouting, and synaptogenesis in the ischemic brain,
explaining the potential for stimulation of brain plasticity
and improvement in functional recovery [36, 37]. In adult
models of stroke, these therapies have been shown to
activate these processes and successfully reduce the size of
the infarcted areas [38, 39] and are now being actively
tested in human patients. The immature brain of a newborn
is not simply a “small adult brain,” and the mechanisms
underlying neonatal HIE is certainly very unique compared
to the ones underlying adult stroke [40]. However, evidence
is growing in the literature that such a systemic approach
might also be useful to better treat neonatal brain injury.
One such potential neurorestorative drug in newborns is
erythropoietin, which has a recognized role in promoting
neural regeneration and neurovascular remodeling [41]. A
randomized controlled clinical trial is currently ongoing
in human newborns to assess its eﬃciency (i.e., “neonatal
erythropoietin in asphyxiated term newborns,” Clinical-
Trials.gov Identiﬁer: NCT00719407). Another promising
alternative treatment of neonatal HIE utilizes cord blood
and mesenchymal stem cells to replace neurons lost due to
brain injury, as well as activate endogenous stem cells, and
release growth factors, thus minimizing brain damage and
promoting restoration [42, 43].
5. What Are the Next Steps before
Implementing These Treatments?
Theseadjunctive therapies have until now mostly been tested
only in animal models of HIE or in diﬀerent populations of
newborns (e.g., erythropoietin to reduce the need for blood
transfusions in very low birthweight infants [44]). Only a
few randomized-controlled studies using these treatments
are currently available in human newborns with HIE, and
they usually include only small numbers of patients [45].
Before implementation, these alternative therapies will need
to prove their eﬃciency and safety in randomized-controlled
clinical trials with appropriate sample size consideration and
outcome variables.
Determining the best timing and the best dosage range
for these alternative treatments is also crucial to obtain
their maximum eﬃciency. It has been hypothesized that
hypothermia may buy additional time for neuroprotective
drugs to act within an expanded “therapeutic window”
[25]. However, for most of these alternative treatments, it
remains to be determined when they will have the maximum
synergistic eﬀect with hypothermia treatment. For example,
in the ﬁrst randomized trial of erythropoietin in term
newborns with HIE, the medication was given ﬁrst within
the ﬁrst 24 hours of birth and thereafter every other day for
2 weeks; the results showed a signiﬁcantly improved primary
outcome (death or disability rate) at 18 months, suggesting
that this medication may provide therapeutic eﬀect over a
longer period than the ﬁrst 6 hours of life [45]. Further
similar trials need to be performed for each of these other
potential treatments.
In addition, appropriate selection of the newborns most
likely to respond to these adjunctive treatments is of utmost
importance to demonstrate more quickly their eﬃcacy.
Planning for such trials should include early identiﬁcation
of newborns at risk of developing brain HI injury (whether
or not hypothermia is administered). To this end, early
biomarkers of future brain HI injury in newborns are
required to adjust existing cooling guidelines or to add
other therapeutic interventions. Ideally, regular evolution
of such biomarkers should be known, so that the impact
of these newer treatments may be assessed as soon as
possible. Current biomarkers included clinical signs, neu-
rological exam outcomes, and assessment of brain activity
by amplitude-integrated electroencephalogram [14, 46, 47].
Recentstudiessuggestsomeotherpotentialbiomarkers,such
as brain magnetic resonance imaging [27], near-infrared
spectroscopy [47], or biochemical markers [48], which
would help guide the adjustment of therapies. Adjustment
of the hypothermia treatment or addition of new treatments
should be performed according to the speciﬁc clinical and
imaging ﬁndings of these patients.
6. Conclusions
How to treat newborns with HIE following birth asphyxia
has become one of today’s hottest topics in neonatal
medicine.Overthepastdecade,substantialprogresshasbeen
made in neurointensive care for newborns. However, much
remains to be done to improve these early positive results
and reduce further the eventual neonatal brain injury and
improve future neurodevelopmental outcome of newborns
with a hypoxic-ischemic event at birth. Several promising
new treatments for the prevention of the devastating neu-
rological consequences of birth asphyxia are currently being
tested, but further detailed animal and clinical studies are
required before their safe application in human newborns
with HIE.
7. FutureResearch Directions
(i) Deﬁne early biomarkers of brain injury to target the
newborns with HIE most vulnerable to brain injury
despite hypothermia treatment.
(ii) Determine if adjustments to current guidelines for
mild hypothermia (i.e., cool later, lower, or longer)
might be useful to further prevent brain injury.4 International Journal of Pediatrics
(iii) Determine the best timing and the best dosage range
of administration of adjunctive treatments, in order
to get their maximum eﬃciency.
(iv) Study in more detail the synergistic eﬀects of these
various treatments to better target the diﬀerent and
speciﬁc needs of each asphyxiated newborn infant
and decrease the eventual neonatal brain injury and
thus improve future neurodevelopmental outcome.
(v) Perform safety studies in human newborns with HIE
for all these potential alternative treatments.
Abbreviation
HIE: hypoxic-ischemic encephalopathy.
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